Compare VECO & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VECO | IRON |
|---|---|---|
| Founded | 1945 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 1996 | 2020 |
| Metric | VECO | IRON |
|---|---|---|
| Price | $49.89 | $68.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $27.25 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 1.1M | 301.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $664,294,000.00 | N/A |
| Revenue This Year | $16.39 | N/A |
| Revenue Next Year | $12.40 | $283.52 |
| P/E Ratio | $87.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.23 | $40.00 |
| 52 Week High | $53.43 | $99.50 |
| Indicator | VECO | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 78.28 | 55.46 |
| Support Level | $28.20 | $57.79 |
| Resistance Level | N/A | $69.36 |
| Average True Range (ATR) | 2.20 | 2.49 |
| MACD | 0.92 | 0.03 |
| Stochastic Oscillator | 78.97 | 50.50 |
Veeco Instruments Inc is a United States-based company engaged in designing, developing, and manufacturing thin-film process equipment, mainly used for producing electronic devices. The company focuses on semiconductor process equipment that addresses a range of challenging materials engineering problems for its customers. Its products include Laser Processing Systems, Lithography Systems, Ion Beam Systems, SiC CVD Systems, MOCVD Systems, Wet Processing Systems, MBE Technologies, Atomic Layer Deposition Systems, Physical Vapor Deposition Systems, Dicing and Lapping Systems, as well as Gas & Vapor Delivery Systems. The maximum of the company's revenue is generated from sales to the Semiconductor Industry and within China.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.